Wilson Sonsini Goodrich & Rosati and Fangda Partners have advised Chinese medical tech platform WuXi AppTec on its $1 billion Hong Kong initial public offering, with Shearman & Sterling and Jia Yuan Law Offices representing the sponsors.

According to Reuters, the listing values the company at $10.2 billion in a deal that marks one of this year’s last big stock offerings in the Asian financial hub.

Hong Kong is poised to become the world’s top IPO centre by volume this year, with $33.2 billion raised so far, Refinitiv data shows.

Shanghai-based WuXi AppTec describes itself as the largest pharmaceutical R&D services platform in Asia by revenue. The company had revenues of 4.41 billion yuan ($641 million) in the first half of this year, versus 3.67 billion yuan in the same period last year, according to its listing prospectus. 

The sponsors included Morgan Stanley Asia Limited, Huatai Financial Holdings (Hong Kong) Limited and Goldman Sachs (Asia). The Shearman team representing them was led by partners Colin Law and Matthew Bersani Law has since moved to Fangda.

美国威尔逊、谢尔曼斯特灵助力药明康德香港上市       

美国威尔逊律师事务所和方达律师事务所助力无锡药明康德新药开发股份有限公司在香港上市，融资逾10亿美元。美国谢尔曼斯特灵律师事务所、嘉源律师事务所担任保荐人的法律顾问。

据路透社报道，该公司上市估值达到102亿美元，成为港交所今年最大规模的IPO之一。

另据路孚特数据显示，香港今年有望成为全球最大的IPO市场，迄今为止总共募资332亿美元。

位于上海的无锡药明康德表示该公司在营收方面已成为亚洲最大的医药研发服务平台。据其招股说明书显示，今年上半年营收为人民币44.1亿元（约合6.41亿美元），去年同期为人民币36.7亿元。

保荐人包括摩根斯坦利亚洲有限公司、华泰金融控股（香港）有限公司和高盛（亚洲）。代表保荐人的谢尔曼斯特灵团队由合伙人罗德源律师和马修•波塞尼律师主导。

To contact the editorial team, please email ALBEditor@thomsonreuters.com.